Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
J Biol Chem. 2010 May 7;285(19):14791-805. doi: 10.1074/jbc.M110.116905. Epub 2010 Feb 23.
CD39 is a transmembrane enzyme that inhibits platelet reactivity and inflammation by phosphohydrolyzing ATP and ADP to AMP. Cyclic AMP (cAMP), an essential second messenger, is particularly important in regulating genes controlling vascular homeostasis. These experiments test the hypothesis that cAMP might positively regulate the expression of CD39 and thereby modulate important vascular homeostatic properties. Cd39 mRNA was induced by 13.8- fold in RAW cells treated with a membrane-permeant cAMP analogue (8-bromo-cyclic AMP; 8-Br-cAMP), stimulation of adenylate cyclase, or prostanoids known to drive cAMP response. Fluorescence-activated cell sorting, immunofluorescence, and TLC assays demonstrated that both CD39 protein expression and enzymatic activity were increased in cells treated with 8-Br-cAMP but not in cells transfected with short hairpin RNA against CD39. This analogue drove a significant increase in transcriptional activity at the Cd39 promoter although not when the promoter's cAMP-response element sites were mutated. Pretreatment with cAMP-dependent protein kinase (PKA), phosphoinositide 3-kinase (PI3K), or ERK inhibitors nearly obliterated the cAMP-driven increase in Cd39 mRNA, protein expression, and promoter activity. 8-Br-cAMP greatly increased the phosphorylation of CREB1 (Ser(133)) and ATF2 (Thr(71)) in a PKA-, PI3K-, and ERK-dependent fashion. Chromatin immunoprecipitation assays demonstrated that binding of phosphorylated CREB1 and ATF2 to cAMP-response element-like sites was significantly increased with 8-Br-cAMP treatment and that binding was reduced with PKA, PI3K, and ERK inhibition, whereas transfection of Creb1 and Atf2 overexpression constructs enhanced cAMP-driven Cd39 mRNA expression. Transfection of RAW cells with mutated Creb1 (S133A) reduced cAMP-driven Cd39 mRNA expression. Furthermore, the cAMP-mediated induction of Cd39 mRNA, protein, and phosphohydrolytic activity was replicated in primary peritoneal macrophages. These data identify cAMP as a crucial regulator of macrophage CD39 expression and demonstrate that cAMP acts through the PKA/CREB, PKA/PI3K/ATF2, and PKA/ERK/ATF2 pathways to control a key vascular homeostatic mediator.
CD39 是一种跨膜酶,通过磷酸水解 ATP 和 ADP 生成 AMP 来抑制血小板反应性和炎症。环腺苷酸 (cAMP) 作为一种重要的第二信使,在调节控制血管稳态的基因方面尤为重要。这些实验检验了 cAMP 可能正向调节 CD39 表达并由此调节重要血管稳态特性的假说。用膜通透型 cAMP 类似物 (8-溴-cAMP;8-Br-cAMP)、刺激腺昔酸环化酶或已知能驱动 cAMP 反应的前列腺素处理 RAW 细胞后,Cd39 mRNA 诱导增加 13.8 倍。荧光激活细胞分选、免疫荧光和 TLC 分析表明,8-Br-cAMP 处理的细胞中 CD39 蛋白表达和酶活性均增加,而用 CD39 短发夹 RNA 转染的细胞则没有增加。该类似物在 Cd39 启动子上驱动转录活性显著增加,尽管当启动子的 cAMP 反应元件位点发生突变时则没有。用 cAMP 依赖性蛋白激酶 (PKA)、磷酸肌醇 3-激酶 (PI3K) 或 ERK 抑制剂预处理几乎消除了 cAMP 驱动的 Cd39 mRNA、蛋白表达和启动子活性的增加。8-Br-cAMP 以 PKA、PI3K 和 ERK 依赖性方式极大地增加了 CREB1(Ser(133))和 ATF2(Thr(71))的磷酸化。染色质免疫沉淀分析表明,用 8-Br-cAMP 处理后,磷酸化 CREB1 和 ATF2 与 cAMP 反应元件样位点的结合显著增加,而用 PKA、PI3K 和 ERK 抑制后则减少,而转染 Creb1 和 Atf2 过表达构建体则增强了 cAMP 驱动的 Cd39 mRNA 表达。用突变的 Creb1(S133A)转染 RAW 细胞可降低 cAMP 驱动的 Cd39 mRNA 表达。此外,在原代腹腔巨噬细胞中复制了 cAMP 介导的 Cd39 mRNA、蛋白和磷酸水解活性的诱导。这些数据表明 cAMP 是巨噬细胞 CD39 表达的关键调节剂,并证明 cAMP 通过 PKA/CREB、PKA/PI3K/ATF2 和 PKA/ERK/ATF2 途径发挥作用,以控制关键的血管稳态介质。